Group 1 - The company, Zhongji Changshou Science (00767.HK), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the largest international autologous immune cell bank in the world [1][2] - Comprehensive Cell Bank is recognized as the only FDA, AABB, PIC/S cGMP, ISBER-IRL, FACT, CAP, and ISBT 128 compliant international clinical cell bank, addressing the global shortage of standard cells and ensuring safe and effective applications [1][2] Group 2 - The Comprehensive Cell Bank is the only FDA-registered immune cell and stem cell bank in Asia, meeting international standards for cell management and storage [2] - The facility, located in Hong Kong, has been operational since November 17, 2018, and possesses patented technologies for cancer early screening, NK cells, stem cells, and chondrocytes, along with 22 advanced medical testing platforms [2] - The target company aims to provide services to over 300,000 individuals globally, with potential revenue exceeding HKD 30 billion from its offerings in immune cell storage, cancer early screening, longevity medical testing, and related cell therapies [2]